Hemostemix Inc(HEM-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.050
Day High0.055
Open:0.055
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Newsfile
Hemostemix' $1,000,000 Private Placement and Update
Newsfile
Upcoming Meeting Dates - April 20, 2026
Newsfile
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Newsfile
Hemostemix Receives FDA Support for Its Basket Protocol Approach
Newsfile
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Newsfile
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Newsfile
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Newsfile
Hemostemix Grants Stock Options
Newsfile
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Newsfile
Hemostemix Welcomes Shaune Harding, OStJ, RN as Director of Patient Care & Clinical Operations
Newsfile
Hemostemix to Attend DFCon San Antonio and Closed its Private Placement
Newsfile
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Newsfile
Dr. William R. Shankle to Advance ACP-01 as a Treatment for Vascular Dementia
Newsfile
Hemostemix Closes CDN$280,594 Private Placement
Newsfile
Hemostemix to Showcase Breakthrough Wound Healing Therapy at Innovations in Wound Care Conference Florida
Newsfile
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Newsfile
Hemostemix Closes Private Placement of $461,230
Newsfile
Hemostemix's Boots on the Ground in Florida October Update
Newsfile
Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI

Profile

Hemostemix Inc is a clinical-stage biotechnology company whose principal business is to develop, manufacture, and commercialize blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments. Its product ACP-01 is derived from a patient's own blood and evaluated in clinical research for ischemic conditions, including Cardiovascular Ischemia, Peripheral Arterial Disease (PAD), Chronic Limb Threatening Ischemia (CLTI), and Vascular Dementia.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.